Nano vesicles discovered in food industry by-products

by IRB Lleida. Institut de Recerca Biomèdica

The research has shown that these vesicles, dubbed BP-EVs, have a high potential to be used as nanovectors for drug delivery. "The finding, which was protected by a European patent last November, indi...

Read more

New advance in porous nanoparticles for drug delivery

by Centro Singular de Investigación en Química Biológica y Materiales Moleculares

The research group BioNanoTools of CiQUS of USC led by Beatriz Pelaz and Pablo del Pino, has just published a paper in the journal Nanoscale that advances in injectable drug delivery systems. The arti...

Read more

Dos estudios con participación de Vall d’Hebron plantean importantes cambios en el tratamiento de los tumores neuroendocrinos

by Vall d’Hebron

Ambos estudios han contado con el apoyo del Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) y son una muestra de como la investigación académica, al margen de la industria farmacéuti...

Read more

Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)

by Minoryx Therapeutics

Minoryx Therapeutics announces that it has filed a Marketing Authorization Application (MAA) for its lead candidate leriglitazone to the European Medicines Agency (EMA) for the treatment of adult male...

Read more

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

by Ysios Capital

Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors

Read more

Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe

by Ysios Capital

Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments for orphan central nervous system (CNS) disorders and the Neuraxpharm Group (“Neuraxpharm”), a leading E...

Read more

La polipíldora recibe el Premio ABC Salud 2022 al mejor medicamento

by Centro Nacional de Investigaciones Cardiovasculares - CNIC

La polipíldora merecedora del premio ABC Salud ha presentado resultados de un estudio que aporta evidencia de una reducción del 33 por ciento en mortalidad por causa cardiovascular.

Read more

El Centro del Cáncer presenta un proyecto de investigación para el desarrollo de un nuevo fármaco mediante inmunoterapia de precisión

by Professional Newco

La investigación trata de desarrollar un nuevo fármaco dirigida a una proteína que se produce en el ambiente tumoral. El fármaco se basa en un anticuerpo frente a esa proteína, que se denomina FA...

Read more

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

by Ysios Capital

VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces it has successfully raised an additional €30 million in a Series B2...

Read more

Cell-derived nanocarriers for more efficient and direct intracelular drug release

by Centro Singular de Investigación en Química Biológica y Materiales Moleculares

This approach led Center for Research in Biological Chemistry and Molecular Materials (CiQUS) researchers to mimic the membrane composition of tumour cells and develop new lipid-based nanocarriers tha...

Read more

Palex and Inbiomotion introduce pioneering test to aid oncologists in predicting recurrence and survival rates in breast cancer patients

by Ysios Capital

The MAF-TEST® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosp...

Read more

El fármaco inclisirán reduce el colesterol con dos inyecciones al año

by Revista Genética Médica

La aprobación del fármaco Leqvio (inclisirán), que permite reducir los niveles de colesterol LDL con dos dosis al año, ha marcado un hito en las estrategias terapéuticas para abordar las enfermed...

Read more
Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Un estudio de INCLIVA muestra el efecto ...

by INCLIVA

Han desarrollado un estudio para evaluar la correlación entre el teji...

Photos Stream